← Eichor
Study identifier: NCT06408441 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)

Condition: Epithelioid Hemangioendothelioma · Sarcoma,Soft Tissue  ·  Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

PhaseN/A
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Epithelioid hemangioendothelioma (EHE) is an ultra-rare sarcoma, marked by distinctive molecular and pathological features and with a variable clinical behavior. Its natural history is still partially understood, reliable prognostic and predictive factors are lacking and many questions are still open on the optimal management. In the context of EURACAN, a prospective registry specifically dedicated to EHE was developed and launched with the aim of providing, through high-quality prospective data collection, a better understanding of this disease. The study design is a registry-based cohort study including only new cases of patients with a pathological and molecularly confirmed diagnosis of EHE. The objectives are to improve the understanding of EHE natural history, validate and identify new prognostic and predictive factors, clarify the activity and efficacy of currently available treatment options, describe treatment pattern. It is an hospital-based registry established in centres with expertise in EHE including adult patients with a new pathological and molecularly confirmed diagnosis of EHE starting from the 1st December 2023. The characteristics of each patient in the facility who meets the above-mentioned inclusion criteria will be collected prospectively and longitudinally with follow-up at cancer progression and / or cancer relapse or patient death. The data analyses will include descriptive statistics and analytical analyses. Multivariable Cox's proportional hazar…

This description comes directly from the study's public registry record.

Talk to the study team

Annalisa Trama, MD  ·  02 2390 3535  ·  annalisa.trama@istitutotumori.mi.it

Melissa Gil Sanjines  ·  02 2390 3564  ·  melissa.gilsanjines@istitutotumori.mi.it

Always discuss trial participation with your own doctor first.

Locations (22)

University Hospital GrazGraz, Graz, AustriaRecruiting
Aarhus University HospitalAarhus, Aarhus, DenmarkRecruiting
Léon Bérard CenterLyon, Lyon, FranceRecruiting
Centre Oscar LambretLille, FranceNot Yet Recruiting
Essen University HospitalEssen, Hesse, GermanyRecruiting
Campus GroßhadernMünchen, GermanyNot Yet Recruiting
Istituto Ortopedico RizzoliBologna, Bologna, ItalyRecruiting
Azienda Ospedaliero Universitaria CareggiCareggi, Firenze, ItalyRecruiting
IRCCS Istituto Clinica HumanitasRozzano, Milano, ItalyRecruiting
Fondazione IRCCS Istituto Nazionale dei TumoriMilan, Milan, ItalyRecruiting
Istituto Oncologico VenetoPadova, Padova, ItalyRecruiting
Policlinico Universitario P. GiacconePalermo, Palermo, ItalyRecruiting

+ 10 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06408441